Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04008186 · ClinicalTrials.gov registry record · Phase 1
A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT04008186 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 61 participants.
The verdict
NCT04008186, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
This study will assess the potential for clinical drug-drug interactions between omaveloxolone and a number of substrates and inhibitors of metabolic enzymes and drug transporters.
Interventions
- DRUG Omaveloxolone
- DRUG Rosuvastatin
- DRUG Midazolam oral solution
- DRUG Repaglinide 1 MG
- DRUG MetFORMIN 500 Mg Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2019-06-14 |
| Est. Completion | 2019-08-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04008186
The ClinicalTrials.gov registry entry for NCT04008186 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Omaveloxolone is the first listed.
NCT04008186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04008186 about?
NCT04008186 is a clinical study titled "A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone". This study will assess the potential for clinical drug-drug interactions between omaveloxolone and a number of substrates and inhibitors of metabolic enzymes and drug transporters.
What is the current status of trial NCT04008186?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2019-06-14. Estimated completion is 2019-08-28.
What interventions are being tested in trial NCT04008186?
The interventions under investigation include: Omaveloxolone (DRUG), Rosuvastatin (DRUG), Midazolam oral solution (DRUG), Repaglinide 1 MG (DRUG), MetFORMIN 500 Mg Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04008186?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.